Lilly says it will raise drug prices in Europe, responding to Trump threats

As the Trump administration works to implement a “most-favored nation” policy, Lilly said it’s “rebalancing” prices to “align” costs across different countries.

Sarepta sells Arrowhead shares as partnership, debt payments loom

Liquidating its stake in Arrowhead helps Sarepta cover a milestone payment and secure what one analyst described as “additional breathing room” ahead of a debt maturity in 2027.

Vedanta, PureTech’s microbiome startup, to cut staff after study setback

The result marks the latest failure for a microbiome therapy in inflammatory bowel disease, which has long been a top target of Vedanta and other companies like it.

Vor says drug licensed from RemeGen succeeded in Sjögren’s study

While Vor provided no details on the results, the company is now evaluating a global trial of the drug in the chronic immune condition.

With FDA PreCheck, drugmakers may get a manufacturing boost

The newly announced program targeting domestic manufacturing is the latest Trump administration move to ramp up drugmaking in the U.S.

AbbVie to build API plant in Illinois as it steps up US production

The expansion is part of AbbVie’s larger $10 billion commitment to U.S. investment in the face of Trump’s tariff threats. 

Expedition, a startup searching for drugs from China, cuts its first deal

The startup agreed to pay Fosun Pharma as much as $645 million for a drug in testing for multiple lung conditions, including bronchiectasis.

Updated Aug. 12, 2025

Insmed gains US approval of lung disease drug forecast to be blockbuster

Brinsupri, which Insmed acquired from AstraZeneca nearly a decade ago, is the first treatment for bronchiectasis that’s not caused by cystic fibrosis. 

PureTech launches new biotech built around lung disease drug

The spinout, known as Celea Therapeutics, will advance what’s designed to be an improved version of the drug pirfenidone for idiopathic pulmonary fibrosis. 

Pfizer looks to expand ADC use after positive bladder cancer data

Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify for chemotherapy.

Bayer buys into KRAS cancer drug; Novartis immune therapy goes 3 for 3

The German pharma will license a KRAS G12D inhibitor from Kumquat Biosciences. Elsewhere, a Biohaven OCD drug missed its study goal, while Biogen and Stoke began a key Phase 3 test.

Vinay Prasad, in surprise reversal, to rejoin FDA after abrupt departure

One analyst speculated that, going forward, Prasad may be less “heavy-handed” in reviewing rare disease therapies given the public backlash to the agency’s confrontation with Sarepta.

Updated Aug. 11, 2025

Novartis drug acquired in Morphosys deal succeeds against tough-to-treat autoimmune disease

The drug, ianalumab, met its objectives in two Phase 3 studies in Sjögren’s syndrome, boosting the outlook of a multibillion-dollar deal that hadn’t yet paid dividends.

IO Biotech sees path forward for skin cancer vaccine despite study setback

A regimen involving the company’s shot failed a Phase 3 trial “by a hair,” an executive said, leading the company to believe it still could win U.S. approval.

As gene therapy sales sputter, one biotech aims to defy the odds

With a strong launch underway for a bladder cancer gene therapy, Ferring is finding the kind of commercial success that’s eluded many of its peers.

BioNTech ends patent fight with mRNA rival CureVac ahead of buyout deal

The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an acquisition of its one-time COVID-19 vaccine competitor.

Inside AstraZeneca’s long-term strategy in lung cancer

Decades-long research has yielded a strong and growing franchise built around drugs for a genetic form of lung cancer.

Elevidys sales weaken; Neumora gets into obesity

Sarepta reported a quarter-on-quarter dip in sales for its Duchenne gene therapy. Elsewhere, Jazz won FDA approval of a brain cancer drug and Novo decided to advance a Prothena medicine into Phase 3.

Iovance cuts staff amid slow sales start for ‘TIL’ cell therapy

In its latest earnings report, Iovance confirmed plans to reduce its workforce by 19% in a bid to save $100 million in yearly costs.

Updated Aug. 8, 2025

Lilly shares fall as obesity pill misses expectations in key trial

While orforglipron succeeded in a Phase 3 trial, its weight loss effects were more modest than investors and analysts anticipated, leading to a selloff in shares that erased about $100 billion in market value. 

FDA to start new ‘precheck’ program to boost US drug production

The initiative is a response to a Trump administration order to speed the construction of the type of new drug factories many pharmaceutical companies have promised to build.

Strand raises another $153M to make ‘programmable’ mRNA drugs

The fundraise will help advance a cancer therapy that’s already shown early promise in people whose cancers haven’t responded to drugs like Keytruda.

FDA lifts pause on Valneva’s chikungunya shot, but adds new limits

The FDA had halted use in older adults while it investigated reports of side effects. The vaccine’s label now carries new warnings and restricts vaccination to individuals at high risk of infection.

Arvinas, Pfizer reworking partnership on ‘Protac’ cancer drug

The smaller market now envisioned for vepdegestrant has changed both companies’ stance on their original deal, leading to negotiations that could either lead to a new alliance or Arvinas to seek a new partner. 

HHS abandons mRNA vaccine research

One vaccine expert called the move, which cancels some $500 million in messenger RNA research contracts, a “giant step backward for science.”